mpact of other adjustments, including stock option expense, depends on whether the amounts are deductible in the tax jurisdictions where the expenses are incurred or the asset is located and the applicable tax rate(s) in those jurisdictions. Due to these factors, the effective tax rates for the adjustments to our GAAP income before income taxes, for the three months and years ended December 31, 2012, were 25.9% and 30.5%, respectively, compared with 34.8% and 21.8% for the corresponding periods of the prior year.Amgen Inc.Reconciliation of GAAP Debt Outstanding to "Adjusted" Debt Outstanding(In millions)(Unaudited)GAAPAdjustments for accounting standard (a)"Adjusted"December 31, 2011
$
21,428$
54$
21,582December 31, 2012
$
26,529$
2$
26,541(a)To exclude the impact of bifurcating the debt and equity components of our convertible notes as required by U.S. accounting standards for these securities commencing in 2009. Reconciliation of Free Cash Flow(In millions)(Unaudited)Three months endedYears endedDecember 31, December 31,2012201120122011Cash Flows from Operations
$
812$
,584$
5,882$
5,119Capital Expenditures
(200)(224)(689)(567)Free Cash Flow
$
2$
,360$
5,193$
4,552Amgen Inc.Reconciliation of GAAP EPS Guidance to "Adjusted" EPS Guidance for the Year Ending December 31, 2013(Unaudited)2013GAAP EPS (diluted) guidance$
.46
-
$
.76Known adjustments to arrive at "Adjusted" earnings*:Amortization of acquired intangible assets
(a)
0.34Stock option expense
(b)
0.04Non-cash interest expense associated with our convertible notes
(c)
0.01"Adjusted" EPS (diluted) guidance$
.85
-
$
7.15*The known adjustments are presented net of their related aggregate tax impact of approximately $0.19 per share. (a)
To exclude the non-cash amortization of intangible assets a
'/>"/>
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Related medicine technology :1.
IRIDEX Announces Preliminary Unaudited Revenues for 2012 Fourth Quarter and Year End2.
MDHI Receives Term Sheet for Working Capital and Acquisition Financing -- Company Hits Profitability on Recurring Revenues3.
Groupe Athena, Inc. Reports Record First Quarter Revenues, Adoption Of IFRS Accounting Standard In Anticipation Of Applying For Listing On The NASDAQ Bulletin Board4.
InfuSystem Holdings, Inc. Reports $14.1 Million of Revenues for the Second Quarter of 2012; Announces Annualized Cost Savings in Excess of $1 million5.
AMILPAR - Revenues Grow 18% and EBITDA Increases 19% in 1H126.
Volcano Corporation Reports 13 Percent Growth In Second Quarter Revenues; FFR Disposable Revenues Increase 38 Percent7.
Amgens Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.838.
CitiusTech Announces H1 2012 Results - 65% Growth in Half Year Revenues9.
Herborium Group Reports Record 6 Month Revenues10.
InfuSystem Holdings, Inc. Reports $14.3 Million of Revenues And $1.6 Million Of EBITDA For The First Quarter Of 201211.
CryoLife Reports Record Quarterly Revenues in First Quarter of 2012